Syros Pharmaceuticals (NASDAQ: SYRS) today announced that new data on its lead candidate, SY-1425, a selective retinoic acid receptor alpha (RARa) agonist, will be highlighted in a late-breaking presentation at the San Antonio Breast Cancer Symposium (SABCS) taking place December 6-10, 2016, in San Antonio. The presentation will feature new preclinical data showing that SY-1425 represents a potentially promising therapeutic approach for defined subsets of breast cancer patients whose tumors are driven by abnormally high expression of the RARA gene. Details on the presentations are as follow: Date & Time: Saturday, December 10, from 7:30 - 9:00 am CSTPresentation Title: A novel subgroup of estrogen receptor positive breast cancer may benefit from super-enhancer guided patient selection for retinoic acid receptor a agonist treatmentSession: Treatment: Novel Targets and Targeted AgentsPresenter: Michael R. McKeown, Ph.D., Senior Scientist, Syros PharmaceuticalsProgram Number: P6-11-18Location: Henry B. Gonzalez Convention Center, Hall 1 SY-1425 is currently in a Phase 2 clinical trial in genomically defined subsets of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients. Using its gene control platform, Syros discovered subsets of AML, MDS and breast cancer patients whose tumors have a highly specialized regulatory region of non-coding DNA, known as a super-enhancer, associated with the RARA gene, which codes for the RARa transcription factor. The super-enhancer is believed to lead to over-expression of the RARA gene, locking cells in an immature, undifferentiated and proliferative state. Treatment with SY-1425 in cancer cells with this super-enhancer promotes differentiation of these cells. About Syros Pharmaceuticals Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros' gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros' lead drug candidates are SY-1425, a selective RARa agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor with potential in a range of solid tumors and blood cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.